ASCL2 and neoplasm: Although a humoral response against the transcription factor Ascl2 was not expected, our results demonstrate the capacity of our vaccine platform to promote a strong humoral response, which is of great interest for developing vaccines against tumor surface antigens, such as Epcam [40] or CEACAM5 [41].